SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Izzy who wrote (2130)10/6/1997 1:06:00 AM
From: Oliver & Co   of 6136
 
Izzy:

I basically start all patients who have a + viral load, or if their CD4 count is less than 500. On combo Rx, usually with triple Rx, however there are many things to take in consideration, you can't practice cookbook therapy on this disease. We think (agoup of HIV Specialists from U of M, and I) that the main reason for the guidelines is to help all those patients who are not being followed by HIV specialists. We do not agree with the notion of starting ALL (100%) of patients on triple Rx.
Remember that we have 11 drugs, and you have to find out if the patient has had Rx before. I always try to have either AZT or D4T on board (CNS)
Prophylaxis- bactrim under 200 cd4, or thrush. Zithromax 1200 QWk, below 50 cd4.
Toxo proph under 200.

Cost ~$12000/yr for 3x Rx.

I do not prescribe PIs, unless I am sure there is going to be supply.
Florida Mcaid pays for all the drugs so far. We do not see HMO.
Viracept ~$100 more than Cryx from what I understand. But you save on IVP's and pain meds.

Hope it helped
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News